Intravenous infusion of high-dose recombinant IL-2 induces CR in approximately 12% of patients with melanoma (63)and 7% of patients with renal cell cancer (RCC) (64), which tends to be durable. Here, IL2 is linked to renal cell adenocarcinoma.